DUAL INHIBITION OF THE TWO SOURCES OF CHOLESTEROL. THE MODERN METHODOLOGY OF REDUCING CARDIOVASCULAR RISC

Abstract

This study evaluated the efficacy and safety of Ezetimibe co-administered with Simvastatine therapy in 104 hypercholesterolemic patients with coronary heart disease (CHD) or diabetes who had not achieved their low-density lipoprotein cholesterol (LDL-C) goal <100mg/dl while on a stable dose of Simvastatine 20mg/day. Significantly more patients achieved an LDL-C goal <100mg/dl with Ezetimibe than Placebo (51% vs. 35%). Compared to Placebo, co-administration of Ezetimibe with Simvastatine led to significantly greater reductions in LDL-C, total cholesterol, triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B; HDL-C was as well increased. Co-administration of Ezetimibe and Simvastatine was well tolerated, with an overall safety profile similar to Simvastatine alone.